You are here

Article Text

Article menu

Download PDFPDF

Lung cancer
Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
  1. Emoke Papp1,
  2. Anita Steib2,
  3. Elhusseiny MM Abdelwahab3,4,
  4. Judit Meggyes-Rapp2,3,
  5. Laszlo Jakab5,
  6. Gabor Smuk6,
  7. Erzsebet Schlegl7,
  8. Judit Moldvay7,8,
  9. Veronika Sárosi1 and
  10. Judit E Pongracz3,4
  1. 1Internal Medicine, Pulmonology, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary
  2. 2Research, Humeltis Ltd, Pecs, Baranya, Hungary
  3. 3Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pecs, Pecs, Baranya, Hungary
  4. 4Szentagothai Research Centre, University of Pecs, Pecs, Baranya, Hungary
  5. 5Surgery, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary
  6. 6Pathology, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary
  7. 7Tumour Biology, National Korányi Institute of Pulmonology, Budapest, Hungary
  8. 8Pulmonology, Semmelweis University, Budapest, Hungary
  1. Correspondence to Dr Judit E Pongracz; pongracz.e.judit{at}pte.hu

Abstract

Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response.

Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period.

Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response.

Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response.

  • non-small cell lung cancer
  • lung cancer chemotherapy
  • lung cancer
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/bmjresp-2019-000505

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All authors contributed to the study design and data analysis, and reviewed and approved the manuscript.

    • Funding This work was supported in part by the University of Pecs KA Research Fund 2018 (to JEP); GINOP-2.3.2.-15-2016-00022, TUDFO/51757-1/2019-ITM and by Humeltis.

    • Competing interests AS and JM-R: employees of Humeltis. JEP: received a grant and personal payments from Humeltis.

    • Patient consent for publication Not required.

    • Ethics approval The project was approved by the Ethical Committee of the University of Pecs (2014-RIKEB-5329-EKK) and the Medical Research Council of Hungary (366/2015 (46945-1/2015/EKU).

    • Provenance and peer review Not commissioned; externally peer reviewed.